Quince Therapeutics Inc Dossier - Source-backed chat

Quince Therapeutics Inc

QNCXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.19

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $30.68Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $31.2M

Enterprise Value −$84.8M

Shares Outstanding 1M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Quince Therapeutics has successfully executed a dramatic strategic pivot following the Phase 3 failure of its former lead asset eDSP in January 2026. By acquiring Orphai Therapeutics in May 2026, Quince added LAM-001—a clinical-stage, inhaled formulation of rapamycin (mTOR inhibitor)—to its pipeline, targeting rare pulmonary diseases with high unmet needs. Paired with a massive private placement of up to $187 million (including $115 million upfront) led by top-tier healthcare investors, Quince has transformed from a cash shell into a well-capitalized, clinical-stage pulmonary player with a cash runway extending through the end of 2028. This capital-rich position, combined with promising Phase 2a data in PH-ILD, presents an attractive risk-reward profile at current valuation levels.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$68.00

Mean target$79.75

High · most bullish analyst$99.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

LAM-001 fails to show efficacy or encounters safety concerns in the ongoing Phase 2 BOS trial or the planned Phase 2b PH-ILD trial. Warrants are not exercised, shortening the cash runway. The company struggles with Nasdaq listing compliance, leading to potential delisting or highly dilutive financing rounds.

Base CaseCentral scenario

Quince successfully initiates the Phase 2b trial of LAM-001 in PH-ILD in mid-2026 and the Phase 2 trial in SAPH in late-2026. The ongoing Phase 2 trial in BOS delivers positive topline data in Q1 2027, triggering the exercise of accompanying warrants to bring in up to $72 million in additional cash. The stock experiences upward re-rating as clinical milestones are met and the cash runway is secured through 2028.

Bull CaseUpside scenario

Successful clinical development and approval of LAM-001 across multiple rare pulmonary indications (PH-ILD, BOS, SAPH), unlocking a multi-billion dollar market opportunity.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated Asset: LAM-001 is a pipeline-in-a-product targeting multiple rare pulmonary indications (PH-ILD, BOS, SAPH) with a disease-modifying mechanism of action (mTOR inhibition) rather than simple vasodilation.
Strong Financial Backing: Upfront gross proceeds of $115 million from a high-quality investor syndicate extend the cash runway through 2028, mitigating near-term funding risks.
Encouraging Early Data: Phase 2a data presented at ATS 2026 showed clinically meaningful improvements, including a 67.4-meter increase in 6MWD and a 33.9% reduction in PVR in PH-ILD patients.

Key Investment Risks

Clinical Development Risk: LAM-001 is in mid-stage development, and positive Phase 2a open-label results may not replicate in larger, placebo-controlled Phase 2b trials.
Regulatory and Listing Risks: The company has previously faced Nasdaq non-compliance notices regarding minimum bid price and market value of listed securities.
Execution Risk: Integrating Orphai's assets and managing multiple clinical trials simultaneously will test the restructured management team.

Thesis Invalidation Triggers

Failure of LAM-001 to meet primary endpoints in the Phase 2 BOS trial expected in Q1 2027.
Inability to initiate the Phase 2b PH-ILD trial on schedule in mid-2026.
Delisting from the Nasdaq Global Select Market due to failure to maintain listing requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.